Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Enterprise software vendors are reorganizing around AI agents and unified data/context layers. Salesforce is buying Braze, ServiceNow is launching a Control Tower Alliance for agent governance, Zoom is adding a context layer, and Confluent is releasing Streamhouse. At the same time, investors such as Norwest see an opening to displace incumbent ERP and finance tools (NetSuite, Sage), while cautioning that AI should not be trusted with finance calculations. Results are uneven: Trimble gave a cautious 2027 outlook, QNX's royalty backlog passed $1.2B, and micro-cap TEN Holdings is still restructuring toward SaaS with small revenue ($640K) and one-off charges.
Late October to early November 2026 announcements show the AI era shifting from model hype to the infrastructure around it. Fortinet, Cisco and T-Mobile are focused on AI security and partner enablement. Encord and Philip Cai Zhenhui describe physical AI as bottlenecked by data and chips. Salesforce is buying Braze for AI-driven customer engagement, and Apple, NVIDIA and ASUS are pushing AI-capable hardware to market. Smaller firms such as TEN Holdings and Impinj are using cost cuts and SaaS-style models to show financial results. The set is only loosely tied to finance, with no direct trading, regulatory or fintech events beyond Intuit's AI product launches and the Salesforce deal.
The 2026 ESMO Congress drove a wave of clinical data, launches and partnerships: Incyte's PDAC collaborations with BMS and Synnovation, Summit's ivonescimab results, AstraZeneca's ZEGFROVY US launch, Astellas' CLDN18.2 real-world evidence, and Abbott's whole-genome MRD test. At the same time, capital-constrained smaller players are restructuring or leaving public markets (Spago's Nasdaq First North delisting, a SkinJect SPAC LOI, ADC Therapeutics' workforce cuts to extend runway into 2028). The result is a bifurcated sector: well-funded leaders and diagnostics/AI-enabled precision oncology are expanding, while micro-caps consolidate or exit.
A sharp Nasdaq selloff on Nov 5, 2026, which erased over $1 trillion from the Magnificent Seven and about $420 billion from Tesla and SpaceX, followed the US midterms and talk that Democrats will rein in Big Tech. Against that, Q3 results from financials (East West, TSLX, FNF, Canara HSBC Life) showed steady fee income, deposit growth and dividends, and J.P. Morgan's aerospace and defense calls show capital rotating toward selective, fundamentals-driven names. AI-finance ties are thin in these facts: Viola FinTech's 40 NYC AI portfolio companies, IEQ Capital's party for AI investors, and a European bank's use of Lenovo edge computer vision point to continued adoption despite the volatility in mega-cap tech.
Q3 2026 earnings and CEO commentary show capital concentrating in AI and defense tech: OpenAI's round closes at about $1.25T, and Shield AI raises $2.5B and buys Echodyne. Media and tech consolidation is moving ahead, with DOJ clearing Fox's purchase of Roku. Credit-market voices such as TSLX's Robert Stanley describe stable spreads, a favorable rate path and an M&A recovery expected in H1 2027 rather than by year-end. Smaller issuers (TEN Holdings, BuzzFeed, Karnalyte) are restructuring and cutting costs while building toward SaaS or development milestones, and DraftKings is spending to acquire customers in prediction markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedStock market today: Dow, S&P 500, Nasdaq trim losses but end sharply lower as Wall Street assesses Iran war worries
“Stock market today: Dow, S&P 500, Nasdaq trim losses but end sharply lower as Wall Street assesses Iran war worries US stocks declined but closed off session lows on Tuesday after Israel and US jets launched new strikes on Iran, as the widening conflict stoked worries about a drawn-out regional war…”
Intel will help build Elon Musk’s Terafab AI chip factory
“The Verge AI - Consumer Ai Title: Intel will help build Elon Musk’s Terafab AI chip factory Date: 2026-04-07 15:43 Source: https://www.theverge.com/transportation/907976/elon-musk-terafab-intel-ai-chip-spacex-tesla <figure> <img alt="Vector illustration of the Intel logo." src="https://platform.theverge.com/wp-content/…”
New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players
“New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players Helsinki, April 05, 2026 (GLOBE NEWSWIRE) -- As Finland’s gambling market moves toward a major regulatory shift, a new comparison platform, Suomi-kasinot.fi, has been launched to help Finnish players navigate the growing number…”
/C O R R E C T I O N - AbbVie/
“/C O R R E C T I O N - AbbVie/ In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made…”
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
“Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 1…”
Tokenization Strategic Outlook Report 2025: Emerging Interconnected Digital Ecosystems
“Tokenization Strategic Outlook Report 2025: Emerging Interconnected Digital Ecosystems Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Tokenization" report has been added to ResearchAndMarkets.com's offering…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Nasdaq plans a 23-hour trading day, Cboe and Robinhood plan company-specific event contracts, and the CFTC is suing states while it weighs 24/7 derivatives. Robinhood's SEC-filed numbers show how large the bet is. The sources behind the surrounding claims are less reliable, and we flag that.
Funding is concentrating on proving who an AI agent is and who it acts for, while incumbents buy and brokers launch new products. SEC-filed figures show Robinhood's revenue rose from $1.865 billion to $4.473 billion in two years. One investor warns AI should not do finance maths.
In its latest quarter Robinhood reported event-contract revenue of $173M, up more than sixfold, while crypto revenue fell 55%. Nasdaq, Cboe and the CFTC are all pushing toward longer trading hours. Every figure here is traced to SEC filings or named documents, and we flag where sources are weaker.
Vor Bio reported two-year Phase 3 kidney results, Incyte's SEC-filed profit rose from $32.6 million to $1.29 billion in a year, and BioArctic's Leqembi royalty grew. Much of the early-stage news rests on company statements. We separate checked figures from claims.
Third-quarter reports split into two stories: a chip-equipment maker guiding to $8.6 billion of quarterly revenue on AI spending, and chemical and rail CFOs trimming costs against fuel and energy. We checked Dow's figures against SEC filings and flag where the evidence is thin.
Third-quarter calls from Lam Research, Dow and Union Pacific show two economies. AI-linked chip demand is outrunning supply, while chemicals and rail protect profit through cost cuts. Every figure is traced to a named speaker, an SEC filing or a source document.
Web Summit Lisbon's edition returns from 9 to 12 November, and the organisers' featured speakers page has a detail still rare at tech conferences: two of the "speakers" are robots.
Dow says its cost-cutting is ahead of schedule while its latest full-year results show the hole it is climbing out of. Union Pacific posted record profit and wants a merger. Both claims come from earnings calls, and the source's measured accuracy is 60%, so we separate what SEC filings confirm from what executives said.
Q3 2026 earnings calls show finance chiefs relying on cost cuts and cash cushions while energy costs stay high. Dow targets $1.3 billion of net benefits and Union Pacific's fuel price rose 64%. The figures come from earnings-call transcripts and SEC-checked filings; we flag where reporting is less certain.
Robinhood's checked SEC figures show revenue up about 2.4 times in two years and a swing from loss to profit. Now it is the first retail broker to offer Cboe's company-performance contracts, while startups raise money to prove AI agents can be trusted. Some of the evidence is thin, and we say where.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.